Netherlands· NL-cb64f328b2ab
Enerzair Breezhaler 114 micrograms/46 micrograms/136 micrograms, inhalatiepoeder in harde capsule
A indacaterol, glycopyrronium bromid und mometason product containing glycopyrroniumbromide + indacaterolacetaat + mometasonfuroaat, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Indacaterol, glycopyrronium bromid und mometason is registered in 11 of 19 countries.
Countries holding a registration under ATC R03AL12 (indacaterol, glycopyrronium bromid und mometason), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Indacaterol, glycopyrronium bromid und mometason · ATC R03AL12
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- GLYCOPYRRONIUMBROMIDE + INDACATEROLACETAAT + MOMETASONFUROAAT
- Manufacturer
- Novartis Europharm Limited
- Country
- Netherlands (NL)
- ATC code
- R03AL12
- ATC class
- Indacaterol, Glycopyrronium bromid und Mometason
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/20/1438
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Indacaterol, glycopyrronium bromid und mometason in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandEnerzair Breezhaler Inha
- SpainENERZAIR BREEZHALER 114 MICROGRAMOS/46 MICROGRAMOS/136 MICROGRAMOS POLVO PARA INHALACION (CAPSULA DURA)Novartis Europharm Limited
- IcelandEnerzair BreezhalerNovartis Europharm Limited*
- PolandEnerzair BreezhalerNovartis Europharm Limited
- CanadaENERZAIR BREEZHALERNOVARTIS PHARMACEUTICALS CANADA INC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a8f3a678-c68d-422c-8e09-1928eced0f8a GET /v1/drugs/a8f3a678-c68d-422c-8e09-1928eced0f8a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Inhalatiepoeder in harde capsule",
"route": "Inhalatie",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/enerzair-breezhaler-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Indacaterol, glycopyrroinium bromide and mometasone",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp125112",
"excipients": [
"CARRAGEENAN (E 407)",
"HYPROMELLOSE (E 464)",
"HYPROMELLOSE (E 464)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ZWART (E 172)",
"INDIGOKARMIJN (E 132)",
"KALIUMCHLORIDE (E 508)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"PROPYLEENGLYCOL (E 1520)",
"ZWARTE INKT"
],
"substances": [
"GLYCOPYRRONIUMBROMIDE",
"INDACATEROLACETAAT",
"MOMETASONFUROAAT"
],
"leaflet_url": null,
"authorised_at": "2020/07/03",
"procedure_number": "EMEA/H/C/005061",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/20/1438",
"additional_monitoring": "N"
}See everything about indacaterol, glycopyrronium bromid und mometason.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.